Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Anti-epileptic Drugs Market – Insights
Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy. The number of available anti-epilepsy drugs (AEDs) have doubled over the past few decades and for the treatment of pediatric epilepsy, nine new drugs were launched in the last decade, as benefits of the medicines are higher than subsequent side-effects from the medicine. Third generation epilepsy drugs (brivaracetam (BRI), carabersat (CRB) and carisbamate (CBM)) are rapidly replacing second and first generation drugs, as they are more safe and tolerable compared to previous generation drugs.
The global anti-epileptic drugs market is estimated to be valued at US$ 7,155.6 million in 2019, and is expected to exhibit a CAGR of 6.6% over the forecast period (2019-2027).
Global Anti-epileptic Drugs Market Share (%) Analysis, By Generation, 2019
Source: Coherent Market Insights Analysis (2020)
Increasing focus of market players on unmet needs of patients with refractory epilepsy is expected to drive growth of the global anti-epileptic drugs market.
The add-on treatments designed by market players for the treatment of epilepsy with fewer side effects at affordable prices are expected to propel demand for novel AEDs. For instance, some of the market players are engaged in the research and development of epilepsy drugs such as Zogenix Inc., INSYS Therapeutics Inc., and Eisai. Moreover, the market players are entering the market with pipeline drugs initially seeking approval from the U.S. FDA as adjunctive therapies in the refractory partial-seizure population, addressing epilepsy patient’s greatest unmet need.
The pipeline drugs are currently in stages of development, and are designed to have fewer drug interactions, improved side effect profiles, and overall enhanced safety. This addresses a major need in the anti-epileptic drug, since most of the old mainstay treatments such as carbamazepine, valproate, and phenytoin, are effective, but have very poor safety profiles and are not well tolerated by pediatric patients.
Global Anti-epileptic Drugs Market – Restraints
However, complementary and alternative medicine (CAM) such as ketogenic diet, modified Atkins diet (MAD), and low glycemic index treatment (LGIT) are widely adopted for the treatment of epilepsy among children, in addition to AEDs, which is expected to hamper the market growth.
For instance, according to the Clinical Nutrition Research (a research study conducted to examine the consumption of nutritional supplements to treat a number of diseases), in 2016, around 30% of the children suffering from uncontrolled epileptic seizures were untreated, worldwide, where ketogenic diet (KD) can be an alternative medical treatment for these children, thus restraining the AED market growth. Furthermore, lack of evidence about the effectiveness of newer and expensive drugs compared to cheaper older compounds is expected to hamper the market growth over the forecast period.
Global Anti-epileptic Drugs Market - Regional Insights
On the basis of region, the global anti-epileptic drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global anti-epileptic drugs market, owing to increasing prevalence of epilepsy and launches of generic drug. For instance, according to the Centers for Disease Control and Prevention, in 2017, around 3.4 million people had active epilepsy in the U.S., which included 3 million adults and 470,000 children. In addition, in August 2019, Dr. Reddy’s Laboratories launched generic anti-epileptic Vigabatrin powder, an oral solution in the U.S. market for the treatment of partial seizure.
Asia Pacific is expected to be the fastest growing region in the global anti-epileptic drugs market, owing to increasing product launches by key players in this region. For instance, in February 2020, Eisai Co., Ltd. launched antiepileptic drug (AED), Fycompa, indicated for adjunctive treatment of partial onset seizures in epilepsy patients aged 12 years and above.
Moreover, in 2016, Daiichi Sankyo Company launched vimpat tablets 50 mg and 100 mg for adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in patients with epilepsy.
Global Anti-epileptic Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027
Source: Coherent Market Insights Analysis (2020)
Global Anti-epileptic Drugs Market - Competitive Landscape
Key players operating in the global anti-epileptic drugs market include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Mylan N.V., Bausch Health Companies Inc., and UCB S.A.